New drug offers hope for patients with Life-Threatening seizures
NCT ID NCT02433314
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This study offered treatment with SAGE-547, a drug given continuously through a vein, to people aged 6 months and older with super-refractory status epilepticus—a severe seizure emergency that does not respond to standard medications. The goal was to see if the drug could safely stop seizures in these critically ill patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUPER-REFRACTORY STATUS EPILEPTICUS are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAGE-547 (a drug given as a continuous IV infusion)
What this could lead to
If it works, this could provide a treatment option for people with super-refractory status epilepticus who have not responded to standard seizure medications.
What could go wrong
This is an expanded access program, not a controlled trial, so results are limited. The drug may not stop seizures in all patients, and side effects are possible.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.